FAQ

AZD8186

Known as: AZD-8186, PI3Kbeta Inhibitor AZD8186 
An inhibitor of the beta isoform of phosphoinositide-3 kinase (PI3K), with potential antineoplastic activity. Upon administration, PI3Kbeta inhibitor… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2015-2017
012320152017

Related topics

Related topics

2 relations

Broader (2)

Aniline CompoundsChromones

Related mentions per year

Related mentions per year

1946-2018
19401960198020002020
AZD8186
Chromones
Aniline Compounds

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Inhibiting PI3Kβ with AZD8186 Regulates Key Metabolic Pathways in PTEN-Null Tumors.
Purpose: PTEN-null tumors become dependent on the PI3Kβ isoform and can be targeted by molecules such as the selective PI3K… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2017
2017
Inhibiting PI3Kb with AZD8186 Regulates Key Metabolic Pathways in PTEN-Null Tumors
Purpose: PTEN-null tumors become dependent on the PI3Kb isoform and can be targeted by molecules such as the selective PI3Kb… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2016
2016
The use of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) as a pathway-specific biomarker with AZD8186, a PI3Kβ/δ inhibitor
BACKGROUND The phosphatidylinositol 3 kinase (PI3K) signalling pathway is frequently altered in human cancer and a promising… (More)
Is this relevant?
2016
2016
Identification of differential PI3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screen
Selective phosphoinositide 3-kinase (PI3K)/AKT/mTOR inhibitors are currently under evaluation in clinical studies. To identify… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2015
2015
Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel.
Loss of PTEN protein results in upregulation of the PI3K/AKT pathway, which appears dependent on the PI3Kβ isoform. Inhibitors of… (More)
  • table 1
Is this relevant?
2015
2015
Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3Kβ and PI3Kδ for the treatment of…
Several studies have highlighted the dependency of PTEN deficient tumors to PI3Kβ activity and specific inhibition of PI3Kδ has… (More)
Is this relevant?
2015
2015
High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
BACKGROUND The phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/AKT pathway is frequently activated during prostate cancer… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?